FDA Approves the First Oral PCSK9 Inhibitor: What Lipfendra Means for Cholesterol Treatment

For the first time, a medicine that blocks PCSK9—a powerful target for lowering LDL cholesterol—is available in tablet form.

The US Food and Drug Administration has approved Lipfendra® (enlicitide), the first oral PCSK9 inhibitor for adults with high cholesterol. The once-daily medication is approved as an addition to diet and exercise for adults with hypercholesterolaemia, including those with heterozygous familial hypercholesterolaemia (HeFH).

Until now, approved PCSK9 inhibitors were administered by injection. The arrival of an oral option represents an important development for patients who require further LDL reduction despite existing cholesterol-lowering treatment.

What is LDL Cholesterol?

Low-density lipoprotein cholesterol, commonly called LDL or “bad” cholesterol, transports cholesterol through the bloodstream.

When LDL levels remain elevated, cholesterol can gradually accumulate inside the walls of the arteries. This contributes to plaque formation, narrowing of the blood vessels and reduced blood flow. If a plaque ruptures, it may trigger a blood clot that can lead to a heart attack or stroke.

High cholesterol usually causes no obvious symptoms. Many people only discover it through a routine blood test known as a lipid profile.

Diet, physical inactivity, excess body weight, certain health conditions and genetics may all contribute to elevated LDL cholesterol.

What Are PCSK9 Inhibitors?

The liver removes LDL cholesterol from the blood using structures called LDL receptors.

A naturally occurring protein called PCSK9 attaches to these receptors and causes them to be broken down. When fewer LDL receptors are available, the liver cannot remove as much LDL cholesterol from the bloodstream.

PCSK9 inhibitors block this process. This allows more LDL receptors to remain active on the liver’s surface, helping the body clear more LDL cholesterol from the blood.

Existing PCSK9 inhibitors have primarily been injectable monoclonal antibody treatments. Lipfendra works through the same biological target but is formulated as a once-daily oral tablet.

What is Lipfendra?

Lipfendra is the brand name for enlicitide, a novel macrocyclic peptide developed by Merck, known as MSD outside the United States and Canada.

The FDA approved Lipfendra 20 mg as an adjunct to diet and exercise for adults with hypercholesterolaemia, including HeFH.

HeFH is an inherited condition that causes very high LDL cholesterol from birth. Because exposure begins early and continues throughout life, people with HeFH face a significantly increased risk of developing premature cardiovascular disease.

Lipfendra may provide another treatment option for adults who still require substantial LDL reduction despite taking the maximum statin dose they can tolerate, with or without other cholesterol-lowering therapies.

It is not intended to replace healthy lifestyle measures. Diet, physical activity, weight management and control of other cardiovascular risk factors remain essential parts of cholesterol management.

How Effective Was Lipfendra in Clinical Trials?

The FDA approval was supported by two randomised, double-blind, placebo-controlled Phase 3 trials involving a combined 3,207 adults. Participants were already receiving maximally tolerated statin therapy and required additional LDL reduction.

CORALreef Lipids

This study included adults with established atherosclerotic cardiovascular disease or an increased risk of developing it.

Participants had an average LDL cholesterol level of 96 mg/dL when the study began. At Week 24, treatment with Lipfendra produced an average 56% reduction in LDL cholesterol compared with placebo.

CORALreef HeFH

This study involved adults with heterozygous familial hypercholesterolaemia.

Participants began with an average LDL cholesterol level of 119 mg/dL. At Week 24, Lipfendra produced an average 59% reduction in LDL cholesterol compared with placebo.

The studies also reported reductions in other cholesterol-related markers, including non-HDL cholesterol and apolipoprotein B.

These findings demonstrate that oral PCSK9 inhibition can produce substantial reductions in LDL cholesterol. However, individual results may vary, and treatment decisions should be based on a patient’s full cardiovascular risk profile.

Does Lipfendra Prevent Heart Attacks and Strokes?

Lowering LDL cholesterol is an established part of reducing cardiovascular risk. Previous cardiovascular-outcomes trials involving statins and injectable PCSK9 inhibitors have demonstrated that LDL reduction can lower the risk of major cardiovascular events in appropriately selected patients.

However, it is important to distinguish this broader evidence from what has been established specifically for Lipfendra.

Lipfendra has been approved based on its demonstrated ability to reduce LDL cholesterol. It is not yet known whether Lipfendra itself reduces cardiovascular events or cardiovascular mortality. A large cardiovascular-outcomes study involving more than 14,500 participants is ongoing.

The cholesterol reductions are therefore highly encouraging, but the long-term cardiovascular-outcomes data are still being evaluated.

What Side Effects Were Reported?

In the larger CORALreef Lipids trial, the frequency of adverse reactions was similar between participants who received Lipfendra and those who received placebo.

In the HeFH trial, the most commonly reported adverse reactions occurring more frequently with Lipfendra were:

• Dizziness: 9% with Lipfendra versus 4% with placebo
• Diarrhoea: 7% with Lipfendra versus 2% with placebo

The proportion of participants who stopped treatment because of adverse reactions was comparable between the treatment and placebo groups.

These trial results do not mean the medicine is appropriate for everyone. A doctor must consider a patient’s medical history, current medications, cholesterol levels, treatment response and overall cardiovascular risk before prescribing any cholesterol-lowering therapy.

Who Could Potentially Benefit?

An oral PCSK9 inhibitor may eventually be considered for adults who:

• Have persistently elevated LDL cholesterol despite lifestyle changes and existing medication
• Have established atherosclerotic cardiovascular disease
• Are considered at high risk of cardiovascular disease
• Have heterozygous familial hypercholesterolaemia
• Require substantial additional LDL reduction
• Cannot achieve their recommended LDL target with their current treatment plan

Not everyone with high cholesterol requires a PCSK9 inhibitor. Statins remain a first-line treatment for many patients, while other options may include ezetimibe, bempedoic acid and injectable PCSK9-targeting therapies.

The most appropriate treatment depends on the individual rather than a single cholesterol result.

Is Lipfendra Available in the UAE?

The announcement relates specifically to approval by the US FDA.

FDA approval does not automatically mean that Lipfendra has been approved, registered or made commercially available in the United Arab Emirates. Medicines require the appropriate local regulatory authorisation before they can be marketed or prescribed in the UAE.

Patients should not purchase this or any prescription medication from unverified online sellers or attempt to import it without confirming the applicable regulations and obtaining medical advice.

What Should Patients Do Now?

The approval of the first oral PCSK9 inhibitor is an important scientific development, but it does not mean that everyone with elevated cholesterol should change treatment.

If you are concerned about your cholesterol, the appropriate first step is to understand your current cardiovascular risk. This may include:

• A complete lipid profile
• Blood pressure assessment
• Blood glucose or HbA1c testing
• Review of family history
• Assessment of smoking, weight and physical activity
• Review of existing conditions and medications
• Evaluation for possible familial hypercholesterolaemia

Do not stop or change a prescribed statin or other cholesterol medication without consulting your doctor.

The MyCare Perspective

Lipfendra represents more than a new tablet. It demonstrates that therapies previously limited to injections may be redesigned into more convenient oral treatment options.

For suitable patients, this could eventually reduce barriers associated with injectable therapy and broaden access to intensive LDL-lowering treatment. Nevertheless, convenience should never replace careful screening, appropriate prescribing and ongoing monitoring.

The most effective cholesterol treatment is not simply the newest medication. It is the treatment that is clinically appropriate, consistently followed and supported by regular monitoring and sustainable lifestyle changes.

Know your numbers. Understand your risk. Treat cholesterol properly.

Sources

• US Food and Drug Administration: FDA Approves First Oral PCSK9 Inhibitor
• FDA: Lipfendra Approval, Clinical Data and Safety Information
• Merck: Lipfendra FDA Approval and CORALreef Clinical Programmer